Pfizer and Keas Partner to Help Consumers Take a More Active Role in Their Health and Wellness

PfizerPfizer and Keas announced today they have entered into an alliance to collaborate on the Keas platform to enable Health and Wellness experts to author, sell and distribute personalized online Care Plans directly to patients. Pfizer and Keas will collaborate to develop care plans and related capabilities that seek to provide consumers, patients and their providers an intuitive, engaging, easy-to-use, and low-cost way to manage their health & wellness, prevention and care delivery.

An asset for both consumers and their physicians, Keas allows users to understand and take charge of their health information by using Care Plans that meet their personal health needs and help extend the reach of their own physicians and health care providers. The Care Plans are authored by leaders in the healthcare industry including doctors, pharmacists, and nutritionists. Among the health experts who have published Care Plans on Keas include Dr. Greene Pediatrics, DiabetesMine, HealthWise, and CVS MinuteClinic.

"Our partnership with Keas demonstrates Pfizer's commitment to invest in innovative and game changing solutions that empower patients and physicians to further engage in the patient's health," said Kristin Peck, SVP of Worldwide Strategy & Innovation. "This is a further testimony of Pfizer's commitment to remain the partner of choice for entrepreneurs and innovators. It is about harnessing the power of the best innovators across the world through new partnerships and novel ecosystems to create a healthier world."

Keas offers a fun, personalized "dashboard" to users giving them the opportunity to keep track of their own health goals and empower them to make decisions about self-care as well as medical care. Keas Founder and CEO Adam Bosworth explains, "Keas helps people take charge of their health, giving them the tools and knowledge required to live a healthy life and tackle such challenges as weight loss, smoking cessation, diabetes prevention or control, heart disease, pediatric issues and even reminders for taking prescriptions or getting lab work done."

"The Pfizer relationship with Keas enables us to partner with health care professionals to extend care management outside the office," said Olivier Brandicourt, President and General Manager of Pfizer's Primary Care Business Unit. "By combining the recommendation of an individual's physician with a personalized, expert-developed Care Plan to support day-to-day health decisions, we believe patients will potentially experience improved health outcomes."

Patients using the interactive platform also will be able to share their Care Plan with a designated provider, following the progress of the patient with the Plan to provide collaborative care. Patients can enroll directly into Care plans or by recommendation of their physician.

About Keas
Keas (www.keas.com) is an interactive service that enables the best medical minds in healthcare to provide individuals with ongoing advice and interpretation about their unique health data - such as lab results and current conditions - and help them take action to achieve their health goals.

Pfizer Inc: Working together for a healthier world™
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Efficacy and safety maintained in patients who swi…

Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]